Inovio Pharmaceuticals clears FDA hurdle, eyes October launch for INO-3107

Inovio Pharmaceuticals has confirmed that the US Food and Drug Administration (FDA) has completed all scheduled pre-licensure inspections for its drug candidate INO-3107, with only one observation reported and subsequently addressed. The clearance marks a significant step toward the company’s Prescribing Drug User Fee Act (PDUFA) target date of 30 October 2026, ahead of which label negotiations with the regulator are anticipated to commence in September 2026.

The biotech firm reported a $13.9 million non-cash gain on warrant liabilities during its second quarter of 2026 earnings, which significantly reduced the reported net loss for the period. This financial position was bolstered by an equity offering completed in July 2026, which generated $18.3 million in net proceeds. Management stated that current cash reserves are sufficient to cover projected launch costs, including pre-launch inventory and marketing spend, extending into late first quarter 2027 without the need for immediate additional capital raises.

Operational focus has shifted decisively toward commercial infrastructure in preparation for the anticipated US launch. Inovio has engaged Syneos Health as a contract sales organization to support distribution efforts. The company’s strategic positioning for INO-3107 emphasises a patient-centric approach that eliminates the requirement for surgical intervention during the dosing window, a key differentiator from the current standard of care. Management believes the drug fulfils accelerated approval criteria by offering meaningful therapeutic benefit through a mechanism of action not impacted by neutralising antibodies.

Looking beyond the immediate launch, Inovio is expanding its DPROT technology platform into rare disease targets, specifically Fabry disease and hypophosphatasia, to drive long-term portfolio growth through partnerships. Positive Phase 3 data from partner ApolloBio in China for VGX-3100 was cited as external validation of the efficacy of Inovio’s DNA medicine platform in treating HPV-related diseases. The company expects to receive seven years of orphan drug market exclusivity if approved, based on its unique delivery method.

Operating expenses decreased by 19 per cent year-on-year, reflecting a strategic consolidation of resources toward the INO-3107 program. For the third quarter of 2026, management estimates an operational net cash burn of $18 million as commercial workstreams ramp up. While the company is awaiting formal FDA feedback on the confirmatory trial design, it maintains that this late-stage review step should not impact the PDUFA timeline or the approvability of the drug.